載入中
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
前收盤價
US$1.41
+US$0.05 · +3.68%
盤中時間採用ET。市場資料可能有所延遲。
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
日內區間
目前US$1.41
52週區間
目前US$1.41
盤中時間採用ET。市場資料可能有所延遲。
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
日內區間
目前US$1.41
52週區間
目前US$1.41
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 7038.7萬 USD | 5934.5萬 USD | 7014.3萬 USD | 1.39億 USD | 1.05億 USD |
| 銷貨成本 | 933.8萬 USD | 1628.8萬 USD | 1280.9萬 USD | 3803.3萬 USD | 2220.9萬 USD |
| 毛利 | 6104.9萬 USD | 4305.7萬 USD | 5733.4萬 USD | 1.01億 USD | 8254.5萬 USD |
| 研究與開發 | 5230.7萬 USD | 4626.3萬 USD | 5888.5萬 USD | 8009.9萬 USD | 5591.9萬 USD |
| 銷售、一般及管理費用 | 4707.4萬 USD | 5514.8萬 USD | 5325萬 USD | 5217.2萬 USD | 4932.3萬 USD |
| 營業費用 | 9938.1萬 USD | 1.02億 USD | 1.25億 USD | 1.35億 USD | 1.05億 USD |
| 利息收入 | 262.5萬 USD | 367萬 USD | 417.2萬 USD | 144.1萬 USD | 45.9萬 USD |
| 利息支出 | 481.3萬 USD | — | — | — | — |
| 折舊和攤銷 | 524.8萬 USD | 494.6萬 USD | 992.3萬 USD | 1025.1萬 USD | 594.7萬 USD |
| 營業利益 | −3833.2萬 USD | −5851.9萬 USD | −6806.9萬 USD | −3488.1萬 USD | −2269.7萬 USD |
| 淨利 | −4397.4萬 USD | −6527.6萬 USD | −7624萬 USD | −3359.2萬 USD | −2127.9萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI523.44萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM350.43萬0.00%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF154.26萬0.00%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO108.55萬0.01%139.17億 USD0.24%US$356.78+0.94%
iShares Biotechnology ETFIBB107.28萬0.01%108.2億 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO84.66萬0.00%180億 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC43.4萬0.03%13.17億 USD0.60%US$183+0.11%
Fidelity Enhanced Small Cap ETFFESM24.39萬—64.1億 USD0.28%US$45.46+0.46%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCFidelity Enhanced Small Cap ETFFESMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
